End-of-day quote
Nasdaq
23:00:00 27/05/2024 BST
|
5-day change
|
1st Jan Change
|
21.92
USD
|
-2.79%
|
|
+0.69%
|
+110.77%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
154.1
|
607.5
|
-
|
-
|
Enterprise Value (EV)
1 |
154.1
|
294
|
89.03
|
607.5
|
P/E ratio
|
-1.23
x
|
-9.44
x
|
-7.96
x
|
-6.37
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
54.5
x
|
333
x
|
307
x
|
224
x
|
EV / Revenue
|
54.5
x
|
161
x
|
45
x
|
224
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-3.77
x
|
-1.04
x
|
-6.19
x
|
FCF Yield
|
-
|
-26.5%
|
-96.3%
|
-16.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
14,818
|
29,349
|
-
|
-
|
Reference price
2 |
10.40
|
20.70
|
20.70
|
20.70
|
Announcement Date
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
2.826
|
1.824
|
1.977
|
2.707
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-48.17
|
-77.53
|
-97.8
|
-130
|
Operating Margin
|
-
|
-1,704.67%
|
-4,251.55%
|
-4,945.61%
|
-4,802.42%
|
Earnings before Tax (EBT)
1 |
-
|
-43.56
|
-63.65
|
-88.36
|
-120.8
|
Net income
1 |
-28.48
|
-43.56
|
-63.65
|
-88.36
|
-120.8
|
Net margin
|
-
|
-1,541.22%
|
-3,490.48%
|
-4,468.65%
|
-4,462.44%
|
EPS
2 |
-7.100
|
-8.450
|
-2.193
|
-2.601
|
-3.252
|
Free Cash Flow
1 |
-
|
-
|
-78
|
-85.74
|
-98.21
|
FCF margin
|
-
|
-
|
-4,277.09%
|
-4,335.68%
|
-3,627.88%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/08/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.924
|
0.457
|
0.874
|
0.3137
|
0.3137
|
0.3137
|
0.319
|
0.319
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.76
|
-12.96
|
-17.84
|
-18.56
|
-19.88
|
-21.26
|
-18.91
|
-19.77
|
Operating Margin
|
-1,705.52%
|
-2,835.01%
|
-2,041.65%
|
-5,917.74%
|
-6,338.14%
|
-6,778.46%
|
-5,927.43%
|
-6,197.34%
|
Earnings before Tax (EBT)
1 |
-14.76
|
-10.56
|
-13.75
|
-14.95
|
-16.33
|
-18.64
|
-15.63
|
-16.58
|
Net income
1 |
-14.76
|
-10.56
|
-13.75
|
-14.95
|
-16.33
|
-18.64
|
-15.63
|
-16.58
|
Net margin
|
-1,597.73%
|
-2,311.38%
|
-1,573%
|
-4,766.47%
|
-5,206.43%
|
-5,942.76%
|
-4,898.43%
|
-5,198.75%
|
EPS
2 |
-3.780
|
-
|
-0.5400
|
-0.5317
|
-0.5767
|
-0.6317
|
-0.5500
|
-0.6033
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/23
|
21/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
314
|
519
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-78
|
-85.7
|
-98.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.13
|
0.18
|
0.21
|
Capex / Sales
|
-
|
-
|
7.02%
|
9.31%
|
7.7%
|
Announcement Date
|
01/08/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
20.7
USD Average target price
49.29
USD Spread / Average Target +138.10% Consensus |
1st Jan change
|
Capi.
|
---|
| +110.77% | 608M | | +8.92% | 114B | | +10.48% | 105B | | -6.45% | 23.83B | | -3.17% | 21.73B | | -10.56% | 18.1B | | -42.36% | 16.34B | | -14.45% | 16.13B | | +3.76% | 13.75B | | +28.94% | 11.76B |
Bio Therapeutic Drugs
|